How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F16%3A10328018" target="_blank" >RIV/00216208:11110/16:10328018 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/16:00088892 RIV/61383082:_____/16:00000205
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037079/pdf/WJG-22-8103.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037079/pdf/WJG-22-8103.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3748/wjg.v22.i36.8103" target="_blank" >10.3748/wjg.v22.i36.8103</a>
Alternative languages
Result language
angličtina
Original language name
How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?
Original language description
The incidence and prevalence of metabolic syndrome (MS) and colorectal cancer (CRC) has been rising in developed countries. The association between these two diseases has been widely studied and reported. Less evidence is available about the relationship between MS and CRC precancerous lesions (adenomatous polyps, adenomas). The aim of this paper is to present an overview of our scientific understanding of that topic and its implication in clinical practice. One of the principal goals of current CRC secondary prevention efforts is to detect and remove the precancerous lesions in individuals with an average CRC risk to prevent the development of invasive cancer. MS is not currently considered a high-risk CRC factor and is therefore not included in the guidelines of organized screening programs. However, in light of growing scientific evidence, the approach to patients with MS should be changed. Metabolic risk factors for the development of adenomas and cancers are the same - obesity, impaired glucose tolerance, dyslipidemia, hypertension, cardiovascular diseases and diabetes mellitus type 2. Therefore, the key issue in the near future is the development of a simple scoring system, easy to use in clinical practice, which would identify individuals with high metabolic risk of colorectal neoplasia and would be used for individual CRC secondary prevention strategies. Currently, such scoring systems have been published based on Asian (Asia-Pacific Colorectal Screening Score; APCS) and Polish populations.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT13673" target="_blank" >NT13673: Targeted colorectal cancer screening in type 2 diabetes patients and high cardiovascular risk patients: multicentric prospective study</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
World Journal of Gastroenterology
ISSN
1007-9327
e-ISSN
—
Volume of the periodical
22
Issue of the periodical within the volume
36
Country of publishing house
CN - CHINA
Number of pages
9
Pages from-to
8103-8111
UT code for WoS article
000383982700005
EID of the result in the Scopus database
2-s2.0-84991089523